drugset / Trial / NCT06490263
the Safety, Tolerability and Pharmacokinetics of Mulberry Twig Alkaloids in Human
Phase 1
Completed
62 enrolled
Beijing Wehand-Bio Pharmaceutical Co., Ltd
Peking University First Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This trial is conducted in China. The aim of the trial is to investigate safety, tolerability, and pharmacokinetics of the Mulberry Twig Alkaloids tablets (WH006) in healthy ，overweight and obesity subjects.
Timeline
- Start
- 2024-05-13
- Primary completion
- 2024-10-19
- Completion
- 2024-11-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mulberry Twig Alkaloids | Unknown | 126 mg | Oral |